Rewriting microenvironment immunity in glioblastoma

The most common primary brain tumor, glioblastoma (GBM), remains uniformly fatal despite surgical resection, radiotherapy, and chemotherapy.1 A major barrier in treating this disease is the presence of myeloid-derived suppressor cells (MDSCs) in the glioma tumor microenvironment.2 These cells are expanded in blood and glioma tissue from patients and are associated with poorer clinical outcomes.3 MDSCs have been well described to suppress T cell activation and proliferation.4 To overcome this disease and its associated immunosuppressive barrier, our group pioneered a novel platform called adoptive cellular therapy (ACT).